Applied Filters
Novartis acquires Japanese generics business in €400m deal
Novartis has agreed to buy the Japanese business of South African generics manufacturer Aspen Pharmacare for a potential €400 million.
Pfizer and Sun settle Bosulif dispute
Pfizer and Indian drugmaker Sun Pharmaceuticals have agreed to settle patent litigation over a generic version of Pfizer’s leukaemia drug, Bosulif.
Takeda sells generics portfolio to Stada for $660m
German pharmaceutical company Stada Arzneimittel has acquired a portfolio of products from Takeda for $660 million.
Global Drug Facility adds new TB drug to its catalogue
The Global Drug Facility, which provides tuberculosis treatments to those in need in 150 countries, has listed a new drug to its product catalogue.
Allergan pays $750m to resolve antitrust litigation
Allergan has reached a $750 million deal to resolve antitrust litigation brought against its subsidiary Forest Laboratories over Alzheimer’s drug Namenda.
Novartis takes aim at Indian drug companies over Entresto generics
Swiss pharmaceutical company Novartis has filed a patent infringement lawsuit against three Indian rivals in a US federal court over proposed generics of its heart failure drug Entresto.
Philippines: fake drugs make up 25% of counterfeits
The National Committee on IP Rights of the Philippines prevented more than PHP455 million worth of counterfeit medicines and personal care products from reaching consumers in the first seven months of this year.
US committee votes in favour of Pelosi’s drug pricing plan
The US House Committee on Energy & Commerce has voted to advance a drug pricing plan which would lower the cost of many prescription drugs.
Fed Circuit rules against Actavis knee pain generic
Actavis Laboratories cannot market a generic version of Horizon Pharma’s knee pain treatment, an appeals court has ruled.
J&J invests $500m into global HIV and TB treatment
Johnson & Johnson has committed $500 million to research and development programmes over the next four years in a bid to eliminate HIV and tuberculosis across the world by 2030.
